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ABSTRACT
Aims Using an established three-dimensional (3D)
toxicological model based on reconstituted human
corneal epithelium (HCE), this study investigated the
tolerability of four topical intraocular-pressure-lowering
agents: the commercial solutions of benzalkonium
chloride (BAC)-containing 0.005% latanoprost, 0.004%
travoprost, 0.03% bimatoprost containing 0.02%, 0.015%
and 0.005% BAC, respectively, and the preservative-free
(PF) taﬂuprost. Solutions of 0.01% and 0.02% BAC alone
were also evaluated for comparison.
Methods The 3D-HCEs were treated with solutions for
24 h followed or not by a 24 h recovery period. We used
a modiﬁed MTT (3(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) procedure to assess cell
viability in the HCE. Frozen sections of HCE were analysed
using ﬂuorescence microscopy for the evaluation of
apoptosis (terminal deoxynucleotidyl transferase
mediated dUTP nick end labelling), inﬂammation
(ICAM-1) and proliferation (Ki67). Corneal epithelial tight
junctions (occludin and tight junction protein 1 (zona
occludens 1)) were also assessed by en face confocal
microscopy in response to the different eye-drops.
Results The MTT test revealed that the cytotoxicity of
antiglaucoma eye-drops was primarily related to the
concentration of their common BAC preservative (0.02%
BAC-latanoprost>0.015% BAC-travoprost>0.005%
BAC-bimatoprost). PF-taﬂuprost did not induce any
obvious cytotoxicity, showed the least expression of
inﬂammatory or apoptotic markers and revealed
preservation of membrane immunostaining of tight
junction proteins in comparison with BAC-containing
solutions.
Conclusion The toxicological model of the 3D
reconstructed corneal epithelia model conﬁrmed the
ocular surface cytotoxicity of BAC-containing
antiglaucomatous solutions. Compared with the
formulations containing the toxic preservative BAC,
PF-taﬂuprost was well tolerated without inducing
signiﬁcant corneal epithelium deterioration.
INTRODUCTION
Taﬂuprost is a newly synthesised prostaglandin
F2a-agonist without any toxic preservative.
1 It
demonstrated no cytotoxicity in human conjunc-
tival epithelial cell lines
2 and was well tolerated
following short- and repeated instillations in
rabbits.
3 The problems raised by potentially toxic
glaucoma treatments should receive more attention
owing to the increased number of patients in the
world, lifespan of treatments that require not only
efﬁcacy, but also safety, good tolerability and
optimal compliance for patients.
Supplied by SkinEthic Laboratories (Nice,
France), the reconstructed three-dimensional (3D)
model of human corneal epithelium (HCE) is an
appropriate alternative toxicological method to the
classical Draize test in rabbits.
4 It was proven to
have the same characteristics as the corneal
epithelium of the human eye in morphology and
thickness, and is suitable for investigating the
undesired effects of ophthalmic drugs.
5 The objec-
tive of this study was to investigate in this
3D-HCE system the tissue changes after the
treatment of the currently available commercial
prostaglandin (PG)-derived eye-drops, namely the
commercial solutions of 0.005% latanoprost,
0.004% travoprost, 0.03% bimatoprost (containing
0.020%, 0.015% and 0.005% of benzalkonium
chloride (BAC), respectively) and preservative-free
(PF) taﬂuprost. We analysed a panel of ﬁve selected
biomarkers in order to assess the phenomena
of apoptosis, inﬂammation, proliferation and
tight junction impairment after a contact with
the different antiglaucoma eye-drops, which
would contribute to a better understanding of
human corneal cell reactions following topical
antiglaucoma treatments.
MATERIALS AND METHODS
Tissue model and antiglaucoma solution treatments
The 3D-HCE model was supplied by SkinEthic
Laboratories and consists of immortalised HCE cells
grown vertically on a 0.5 cm
2 insert permeable
polycarbonate ﬁlter. All the experiments were
conducted as previously published
5:3 0ml of sterile
phosphate-buffered saline (PBS) used as a negative
control solution, BAC solutions at 0.020%
and 0.010% used as positive controls and the
commercial solutions of 0.020% BAC-containing
latanoprost (Xalatan; Pﬁzer, New York), 0.015%
BAC-containing travoprost (Travatan, Alcon,
Texas), 0.005% BAC-containing bimatoprost
(Lumigan, Allergan, California) or PF-taﬂuprost
(Taﬂotan, Santen Oy, Tampere, Finland) were
applied on the apical surface of 3D-HCE for 24 h
and 24 h followed by an additional 24 h recovery
period (24 h+24 h recovery). The recovery period
(24 h) was chosen in order to observe if toxic effects
on HCE were reversible or not.
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Laboratory scienceSixseries of3D-HCEwere usedforeach solution: twoseries for
cell viability MTT (3(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide) testing, two series for immunohistological
analyses on cryosections, and two series for immunoﬂuorescent
labelling on the most superﬁcial layers of 3D-HCE by en face
confocal microscopic analyses.
Modiﬁed MTT test
The experiments were conducted in triplicate. The 3D-HCEs
were transferred to 24-well plates containing 300 ml of the MTT
solution at 0.5 g/ml in culture medium with the application
onto the apical surface. After the 3 h incubation at 378C, the
3D-HCEs were incubated with 750 ml of isopropanol. After
agitation for 2 h, the results were analysed by the optical density
(OD, absorbance) at 570 nm versus OD690 nm and expressed as
a percentage of cell viability compared with the negative control,
PBS. Analyses were performed using Saﬁre technology
(Tecan, Lyon, France).
Immunoﬂuorescence analyses
After incubations with different solutions, the 3D-HCE samples
were transferred into Petri dishes containing PBS to be separated
into two pieces using a surgical scalpel. One piece of tissue was
embedded in optimal cutting temperature embedding medium
(Tissue-Tek, Miles, Elkhart, Indiana) and frozen at 808C for
future 10 mm vertical cryosections. The other piece was ﬁxed in
4% paraformaldehyde (PFA) for 20 min before immunoﬂuores-
cent labelling of the tight junction proteins occludin and tight
junction protein 1 (zonula occludens 1, ZO-1).
Detection of apoptosis (terminal deoxynucleotidyl transferase
mediated dUTP nick end labelling (TUNEL) assay), inﬂammation
(CD54) and proliferation (Ki67) on 3D-HCE cryosections
Apoptosis and TUNEL assay
A TUNEL kit containing TUNEL enzyme and TUNEL label
(Roche Diagnostics, Meylan, France) was used to detect
apoptosis in the tissue layers. The nuclei were labelled with
4’,6-Diamidino-2-phenylindole dihydrochloride, and the cryo-
sections were mounted in an antifade medium (Vectashield;
Vector Laboratories, Burlingame, California).
CD54 (ICAM-1) and Ki67 immunostainings
The samples were ﬁrst ﬁxed with 4% PFA for 10 min and then
permeabilised with 0.01%-diluted Triton X100 (Sigma Chemical
Company, Saint Louis, Missouri) for 5 min. The following
primary antibodies were incubated: mouse antihuman ICAM-1
(IgG1, BD Biosciences, Pharmingen, San Diego, California;
1:100), mouse antihuman Ki67 (Immunotech, Marseilles,
France; 1:25) and negative isotypic control mouse IgG1 (BD
Biosciences). Alexa 488 conjugated-goat antimouse IgG at
a 1:500 dilution (Invitrogen-Molecular Probes, Eugene, Oregon)
was used as a second antibody. The nuclei were labelled with
propidium iodide (PI) and cryosections were mounted. Samples
were analysed under a laser confocal microscope equipped with
a digital camera (E800, PCM 2000; Nikon, Champigny-sur-
Marne, France). The immunopositive cells were counted under
a 320 objective of the microscope in three different areas, and
the results were calculated as the average of counts, and ﬁnally
presented as cells/ﬁeld (320 objective) after each treatment.
Confocal immunoﬂuorescence on entire epithelia for tight junction
staining
The rabbit antihuman occludin (IgG1, Dako, Glostrup,
Denmark; 1:100 dilution) and rabbit antihuman ZO-1 (IgG1,
Santa Cruz Biotechnology, Santa Cruz, California) were used for
tight junction staining. Alexa 488-conjugated goat antimouse
was used as a second antibody, and ﬁnally nuclei were labelled
with 49,6-diamidino-2-phenylindole. Samples were then
analysed under a laser confocal microscope (E800, PCM 2000,
Nikon) for detecting occludin and ZO-1 expressions.
Quantiﬁcation and statistical analysis
TUNEL-, ICAM-1- and Ki67-positive cells were quantiﬁed
manually, using a microscopic grid on images under 3400
magniﬁcation. The results were expressed as mean cell number
per ﬁeld (cells/ﬁeld). SDs were indicated.
Control and treatment groups for MTT data and immuno-
positive cell counts were compared using a two-way analysis of
variance (ANOVA) followed by the Fisher adjustment (Statview
V; SAS Institute, Cary, North Carolina).
RESULTS
Cell viability: MTT test
PBS that was used as negative control did not affect the cell
viability either at 24 h or at 24 h+24 h recovery (ﬁgure 1).
PF-taﬂuprost showed the same level of cell viability as PBS at
24 h (90.2%) and at 24 h+24 h recovery (100%) without any
statistically signiﬁcant differences compared with PBS. The
preservative solutions of BAC at 0.010% and 0.020% induced
a cell viability decrease at 24 h (65.9% and 42.5% respectively,
p<0.01 compared with PBS) and at 24 h+24 h recovery (62.9%
and 43.4% respectively, p<0.01 compared with PBS).
The preservative-containing antiglaucoma solutions induced
a BAC-concentration-dependent decrease in cell viability: at
24 h, 85.5% for 0.005% BAC-bimatoprost, 75.5% for 0.015%
BAC-travoprost (p<0.01 compared with PBS group) and
Figure 1 Cell-viability MTT 3(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide) test: cell viability of phosphate-buffered saline (PBS)-,
preservative-free (PF)-taﬂuprost-, 0.005% benzalkonium chloride (BAC)-
bimatoprost-, 0.010% BAC-, 0.015% BAC-travoprost-, 0.020% BAC-
latanoprost- and 0.020% BAC-treated 3D-human corneal epithelium after
24 h incubation without or with a 24 h recovery period. Antiglaucoma
treatments induced a BAC-dose-dependent decrease in cell viability as
assessed by the MTT test. PF-taﬂuprost showed a higher level of
viability than all BAC-containing eye-drops. *p<0.01 compared with
PBS at the same time point; #p<0.03 compared with 0.010% BAC at
the same time point; $p<0.002 or p<0.03 ($$) compared with 0.020%
BAC at the same time point; Ap<0.05 compared with 0.020% BAC-
latanoprost at the same time point; Cp<0.02 compared with 0.015%
BAC-travoprost at the same time point.
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Laboratory science40.1% for 0.020% BAC-latanoprost (p<0.05 compared
with PF-taﬂuprost, 0.005% BAC-bimatoprost and 0.015%
BAC-travoprost groups, p<0.01 compared with PBS and p<0.05
compared with 0.010% BAC group), at 24 h+24 h recovery,
83.0% for 0.005% BAC-bimatoprost, 65.5% for 0.015% BAC-
travoprost (p<0.01 compared with PBS group, p<0.02
compared with PF-taﬂuprost group) and 53.2% for 0.020% BAC-
latanoprost (p<0.05 compared with PF-taﬂuprost and 0.005%
BAC-bimatoprost).
Immunoﬂuorescence analyses and quantiﬁcation of apoptosis
(TUNEL)
Few apoptotic cells were observed after PBS (ﬁgure 2A) or PF-
taﬂuprost (ﬁgure 2B) incubations (ﬁgure 2H): 17.0 cells/ﬁeld for
PBS and 13.3 cells/ﬁeld for PF-taﬂuprost at 24 h; 14.5 cells/ﬁeld
for PBS; and 15.4 cells/ﬁeld for PF-taﬂuprost at 24 h+24 h
recovery. In accordance with our previous study, BAC at
0.010% and 0.020% signiﬁcantly increased the number of
TUNEL-positive cells at 24 h, and at 24 h+24 h recovery
compared with PBS group (p<0.02 for 0.010% BAC, p<0.01 for
0.020% BAC).
The number of apoptotic cells increased after the BAC-
containing antiglaucoma eye-drops in a BAC-concentration-
dependent manner at 24 h. In addition, the corneal epithelial cells
could not recover after the recovery period, and more cells tended
to undergo apoptosis with an increase in TUNEL-positive cells at
24 h+24 h recovery. Bimatoprost with 0.005% BAC (ﬁgure 3C)
induced moderate expression of apoptosis (ﬁgure 2H, 23.4 cells/
Figure 2 Apoptosis analysis:
localisation of terminal deoxynucleotidyl
transferase mediated dUTP nick end
labelling (TUNEL)-positive cells (green)
on 3D-human corneal epithelium
samples after phosphate-buffered saline
(PBS) (A), preservative-free (PF)-
taﬂuprost (B), 0.005% benzalkonium
chloride (BAC)-bimatoprost (C), 0.010%
BAC (D), 0.015% BAC-travoprost (E),
0.020% BAC-latanoprost (F) and 0.020%
BAC (G) incubation after 24 h without
(left column) or with the 24 h recovery
period (right column). Quantiﬁcation of
TUNEL-positive cells (H) was performed
after 24 h of treatment with all solutions
followed or not by a 24 h recovery
period. At 24 h or 24 h+24 h recovery,
no or very few apoptotic cells were
observed after PBS (A) or PF-taﬂuprost
(B) treatments. Bimatoprost with
0.005% BAC (C) induced moderate
expression of apoptosis, and 0.010%
BAC (D), 0.015% BAC-travoprost (E),
0.020% BAC-latanoprost (F) 0.020%
BAC (G) all induced a great number of
TUNEL-positive cells principally in the
apical cell layers, and also in the middle
epithelial layers. The nuclei were
stained with 49,6-diamidino-2-
phenylindole (blue). The quantiﬁcation
of TUNEL-positive cells shows the
increase in apoptotic cell number in
a BAC dose-dependent manner. BAC at
0.010% and 0.020% signiﬁcantly
increased the number of TUNEL-positive
cells at 24 h, and at 24 h+24 h
recovery compared with control. The
antiglaucoma eye-drops travoprost and
latanoprost, which contain higher
concentrations of BAC, showed a much
higher expression of apoptotic cells
than did PF-taﬂuprost or control.
*p<0.02 for 0.010% BAC and p<0.01
for other solutions compared with PBS
at the same time point; #p<0.005
compared with 0.010% BAC at the
same time point; $p<0.001 compared
with 0.020% BAC at the same time
point; Ap<0.003 compared with
0.020% BAC-latanoprost at the same
time point; Cp<0.03 compared
with 0.015% BAC-travoprost at the same time point.
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Laboratory scienceﬁeld at 24 h and 24.8 cells/ﬁeld at 24 h+24 h recovery), and
0.015% BAC-travoprost (ﬁgure 2E) with 37.0 cells/ﬁeld at 24 h
and 42.6 cells/ﬁeld at 24 h+24 h recovery (p<0.03 compared
with PF-taﬂuprost and 0.005% BAC-bimatoprost groups at 24 h
and 24 h+24 h recovery). The highest levels of apoptotic cells
were found homogenously disseminated after the application of
0.020% BAC-latanoprost (ﬁgure 2F) and of 0.020% BAC
(ﬁgure 2G): 43.4 cells/ﬁeld and 44.3 cells/ﬁeld respectively at
24 h; 68.3 cells/ﬁeld and 61.3 cells/ﬁeld respectively at 24 h+24 h
recovery. These TUNEL-positive cells were observed especially in
the apical cell layers, but also in the middle epithelial layers.
Latanoprost with 0.020% BAC induced a signiﬁcantly higher
amount of apoptotic cells than did PF-taﬂuprost, 0.005% BAC-
bimatoprost at 24 h (p<0.003 for both) and 24 h+24 h recovery
Figure 3 Inﬂammation analysis:
immunolocalisation of ICAM-1 (CD54)
positive cells (green) on 3D-human
corneal epithelium samples after
phosphate-buffered saline (PBS) (A),
preservative-free (PF)-taﬂuprost (B),
0.005% benzalkonium chloride (BAC)-
bimatoprost (C), 0.010% BAC (D),
0.015% BAC-travoprost (E), 0.02% BAC-
latanoprost (F) or 0.020% BAC (G)
treatments after 24 h of treatment
without or with the 24 h postincubation
period. Quantiﬁcation of ICAM-1 (H)
was performed after 24 h of treatment
with all solutions followed or not by
a 24 h postincubation period. ICAM-1-
expressing cells were already found in
the PBS (A) and PF-taﬂuprost (B)
groups with the same level of
expression after 24 h or 24 h+24 h.
The increase in ICAM-1 expressions
was observed after the treatments with
0.005% BAC-bimatoprost (C) and
0.010% BAC (D) with and without the
24 h postincubation period. However,
few remaining ICAM-1 positive cells
were observed after treatments with
0.015% BAC-travoprost (E), 0.020%
BAC-latanoprost (F) and 0.020% BAC
(G) on the 3D-human corneal epithelium
samples owing to the erosion. The
nuclei were stained with propidium
iodide (red). The quantiﬁcation of
terminal deoxynucleotidyl transferase
mediated dUTP nick end labelling-
positive cells conﬁrmed the
observations. *p<0.001 compared with
PBS at the same time point; #p<0.005
compared with 0.010% BAC at the
same time point; $p<0.0001 compared
with 0.020% BAC at the same time
point; Ap<0.002 compared with
0.020% BAC-latanoprost at the same
time point; Cp<0.008 compared with
0.015% BAC-travoprost at the same
time point.
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Laboratory science(p<0.003 for both), as well as 0.010% BAC and 0.015%
BAC-travoprost at 24 h+24 h recovery (p<0.003).
Immunoﬂuorescence analyses and quantiﬁcation of the
inﬂammation marker: ICAM-1 (CD54)
PBS-treated 3D-HCE cultures (ﬁgure 3A,H) were found to
express CD54 at levels of approximately 113.2 cells/ﬁeld at 24 h,
and 74.0 cells/ﬁeld at 24 h+24 h recovery. PF-taﬂuprost induced
121.5 cells/ﬁeld at 24 h and 79.0 cells/ﬁeld at 24 h+24 h recovery
without any statistically signiﬁcant differences with PBS-treated
samples. BAC 0.005%-bimatoprost induced an increase in CD54-
positive cells: 155.5 cells/ﬁeld at 24 h and 134.0 cells/ﬁeld at 24 h
+24 h recovery (p<0.001 compared with PBS, p<0.002
compared with 0.02% BAC-latanoprost, p<0.008 compared
with 0.015% BAC-travoprost at 24 h and 24 h+24 h recovery).
This level of increased CD54 activation was also found with
0.01% BAC: 158.8 cells/ﬁeld at 24 h, and 128.5 cells/ﬁeld at 24 h
+24 h recovery (p<0.001 compared with PBS, p<0.002
compared with 0.02% BAC-latanoprost, p<0.008 compared
with 0.015% BAC-travoprost at 24 h and 24+24 h recovery).
For 0.005% BAC-bimatoprost and 0.010% BAC, the CD54
positive cells were located throughout all the epithelial layers
(ﬁgure 3C,D). However, with higher concentrations of BAC, this
number decreased, probably owing to the erosion of corneal
epithelium with toxic solutions: 74.0 cells/ﬁeld after 0.015%
BAC-travoprost treatment, 73.3 cells/ﬁeld after 0.020% BAC-
latanoprost treatment and only 64.3 cells/ﬁeld after 0.020% BAC
treatment at 24 h (for the three groups: p<0.001 compared with
PBS group, p<0.005 compared with 0.010% BAC).
Immunoﬂuorescence analyses of cell proliferation: Ki67
After PBS treatment (ﬁgure 4A), some proliferating cells were
observed, not restricted to the basal layer at 24 h or 24 h+24 h
recovery. PF-taﬂuprost induced a similar aspect as did PBS-
treated samples. However, more numerous proliferating cells,
with a greater number located in the basal layer, were found
after 0.005% BAC-bimatoprost (ﬁgure 4C), 0.01% BAC
(ﬁgure 4D), 0.015% BAC-travoprost (ﬁgure 4E), 0.02% BAC-
latanoprost (ﬁgure 4F) and 0.02% BAC (ﬁgure 4G). At 24 h+24 h
recovery, we could still ﬁnd some proliferative cells after the
treatments with PBS or PF-taﬂuprost. In this time, following
treatment with the solutions containing BAC (0.010% BAC,
0.020% BAC, and the three BAC containing antiglaucoma
solutions), no or very few proliferative cells were observed, again
most likely owing to the deep impairment of corneal cells after
toxic challenge.
En face confocal microscopic analysis of tight junction: occludin
and ZO-1
The 3D-HCEs revealed a thin occludin immunostaining in the
most superﬁcial cells, forming a persistent green ring around,
leaving a diffuse cytoplasmic staining, after treatments with
PBS (ﬁgure 5A) or PF-taﬂuprost (ﬁgure 5B). We still found
a slight occludin expression in the apical cells with 0.005% BAC-
bimatoprost (ﬁgure 5C). This kind of occludin expression clearly
disappeared after treatments with 0.010% BAC (ﬁgure 5D),
0.015% BAC-travoprost (ﬁgure 5E), 0.020% BAC-latanoprost
(ﬁgure 5F) and 0.020% BAC (ﬁgure 5G) at 24 h, leaving only
dense green patches. After the 24 h recovery period, no signiﬁcant
change in occludin protein distribution was found compared
with treatment without the recovery period. The same tendency
was found using ZO-1: a thin green ring was found just after the
treatment with PBS (ﬁgure 5H) or PF-taﬂuprost (ﬁgure 5I).
DISCUSSION
The toxicological model of 3D-reconstructed cornea epithelial
model conﬁrmed the cytotoxicity of BAC-containing solutions
with a better approach of what exists in vivo or in vitro. Using
a selection of pertinent biomarkers on this 3D-HCE, we detected
and analysed the presence of cell apoptosis, activation/inﬂam-
mation, proliferation/turnover and cellular tight junctions after
application of different test solutions. This model, while
respecting the ethical guidelines of animal experimentation,
especially the ‘3R’ rule (reﬁning, reducing and replacing the use
of animals),
6 contributes to a better visualisation of the
human epithelial structure than the traditional monolayer cell
Figure 4 Proliferation analysis:
immunolocalisation of Ki-67 positive
cells (green) on 3D-human corneal
epithelium samples after phosphate-
buffered saline (PBS) (A), preservative-
free (PF)-taﬂuprost (B), 0.005%
benzalkonium chloride (BAC)-
bimatoprost (C), 0.01% BAC (D),
0.015% BAC-travoprost (E), 0.020%
BAC-latanoprost (F) or 0.020% BAC (G)
treatments after 24 h of treatment
without (left column) or with the 24 h
recovery period (right column). Ki67
immunostaining showed an epithelium
with proliferating cells not restricted to
the basal layer after PBS treatment (A)
at 24 h. The same aspect was found
after the treatment of PF-taﬂuprost (B).
Numerous proliferating cells, with
a great number located in all the layers,
were found after the treatments of
0.005% BAC-bimatoprost (C), 0.010%
BAC (D), 0.015% BAC-travoprost (E),
0.020% BAC-latanoprost (F) and 0.020%
BAC (G) at 24 h. At 24 h+24 h recovery, we observed the persistence of some proliferative cells after the treatments of PBS or PF-taﬂuprost.
However, at this time, there were no more proliferative cells after the treatments with all BAC-containing solutions.
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Laboratory sciencecultures and represents a highly valuable tool between
animal and cellular models for toxicity detection. The ﬂuores-
cence techniques conjugated with confocal microscopy on 3D-
reconstructed corneal epithelia were proven to be suitable for the
investigation of toxicological markers and yielded relevant
results compared with the known human data.
5 As on mono-
layer cell cultures, the 24 h recovery experiments on 3D-HCE
model allow the apoptotic process to develop further and to
induce the inhibition of proliferation. The expression of the
proliferation marker, KI-67 nuclear antigen decreased after this
24 h recovery, while the apoptosis- and inﬂammation-related
markers increased. These results conﬁrmed that BAC, depending
on the time and concentration used, acts as a pro-inﬂammatory
and pro-apoptotic agent able to impair the normal epithelium
turnover irreversibly, even after BAC withdrawal. Several in
vitro studies have already revealed these deleterious effects of
BAC and BAC-containing antiglaucoma drugs. The MTTassay is
a simple quantitative method usually used to assess the cell
viability in these 3D-HCE models.
7 It seems more reliable and
robust than immunoﬂuorescence and confocal microscopy,
which are known to provide visual and convincing results for
the analysis of cell damage; however, these techniques are
deemed to give adjunct results for the purpose of comparison of
tested solutions. But, even if based on a smaller number of cells
and a quantitative reading that depends on the experimenter, we
proved in this study that these techniques also allow quantiﬁ-
cation and provide a good understanding of all toxic phenomena
and their impact on various biological processes. Consistent
with similar analyses in monolayer cell cultures and in the rabbit
model, in the present study using this new 3D model, we
demonstrated that PF-taﬂuprost presented almost the same
aspects as did the negative control with persistent epithelial cell
tight junctions and the appropriate proliferative level, with no
induction of cellular apoptosis or inﬂammation when compared
with the formulations containing toxic preservative BAC. BAC-
induced ocular toxicity has been well documented in cell culture,
animal models and patients.
8 The reconstituted 3D-HCE model,
resembling the corneal epithelium of the human eye in
Figure 5 Tight junction: occludin and tight junction protein 1 (zona occludens 1, ZO-1). Immunoﬂuorescence analysis of occludin (green: A to G) and
ZO-1 (green: H to N) expressions using en face confocal microscopy after treatment with phosphate-buffered saline (PBS) (A), preservative-free (PF)-
taﬂuprost (B), 0.005% benzalkonium chloride (BAC)-bimatoprost (C), 0.010% BAC (D), 0.015% BAC-travoprost (E), 0.020% BAC-latanoprost (F) and
0.020% BAC (G) treatments after 24 h (left column) or 24 h+24 h recovery (right column). The nuclei were stained with 49,6-diamidino-2-phenylindole
(blue). After the treatment with PBS or PF-taﬂuprost, the 3D-human corneal epithelium revealed a thin occludin/ZO-1 immunostaining in the most
superﬁcial cells of samples by forming a green ring around, leaving a diffuse cytoplasmic staining. We still found a slight tight junction expression in the
apical cells with 0.005% BAC-bimatoprost (C). The expressions disappeared completely after the treatments with 0.010% BAC (D), 0.015% BAC-
travoprost (E), 0.020% BAC-latanoprost (F) and 0.020% BAC (G) at 24 h or 24 h+24 h recovery, leaving dense green patches. Note that the nuclei
became smaller after treatments with high-dose BAC-containing solutions.
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Laboratory sciencemorphology and thickness,
9 was already used as a new alter-
native to the classic Draize eye test for the assessment of the eye
irritation potential of chemicals and cosmetic products.
41 0It
conﬁrmed the cytotoxicity of BAC, and this model was sensitive
enough to distinguish between different concentrations of BAC,
from 0.001% to 0.5%.
5 The versatility and sensitivity of the 3D-
HCE models were also investigated, and this model was
proposed to replace some uses of animal testing in preclinical
studies. In addition, the occludin gene expression was proposed
as an early in vitro sign for assessment of mild eye irritation.
11
Even though multiple studies consistently showed BAC
toxicity and potential advantages of BAC-free compounds,
8
there still exists some debate as to its cytotoxicity in ocular
tissues and potential harmfulness for glaucoma patients. In
contrast with our results and all literature data on BAC,
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one recent study did not ﬁnd any loss of viability when testing
BAC alone or BAC-containing latanoprost after a short contact
duration from 10 to 60 min using the same model of 3D-
corneal epithelium as that used in this study.
20 These
conﬂicting results were principally due to the differences in
experimental conditions, such as the choice of model or
a p p r o p r i a t e n e s so fd u r a t i o no fc o n t a c t .I np a t i e n t s ,t h ea g e ,t h e
quality of tear ﬁlm, the individual sensitivity of the ocular
surface, a pre-existing sensitivity or allergy, and the overall
number of BAC-containing eye-drops and duration of admin-
istration could all be considered to inﬂuence the impact of toxic
preservative on ocular tissues and may explain wide individual
variations. In experimental conditions, the contact duration of
BAC is essential to consider and may explain some apparently
conﬂicting results: Khoh-Reiter and Jessen stated in their study
that BAC is in contact with the eye structures only for a few
seconds after instillation. Another study proved that a rapid
dilution in the tear ﬁlm reduced the concentration of BAC to
almost zero in minutes.
21 However, Champeau et al detected
t h ep r e s e n c eo fB A Ci nt h ec o n j u n c t i v a le p i t h e l i u m9d a y sa f t e r
a single administration, which suggests prolonged impregna-
tion of BAC in ocular tissue instead of simple dilution in tear
ﬁlm.
22 In rabbits, radiolabelled BAC was found in the palpebral
and bulbar conjunctiva and all corneal layers, and single-drop
administration resulted in high tissue levels in the anterior
ocular tissues remaining for up to 120 h.
23
In our model of a 3D culture of corneal epithelium, a 24 h
incubation was therefore considered to better mimic the accu-
mulation of BAC over the long term and allowed a better
investigation of the cell alterations in the deeper layers of the
corneal epithelium. As BAC is usually considered a potent and
useful enhancer of drug penetration into deep ocular structures,
all experimental models should be considered in light of
a signiﬁcant contact time, depending not on tear concentrations
of BAC but on much more prolonged contact times, as most
likely occurs with a compound that impairs the tear ﬁlm,
disrupts cell membranes, increases corneal epithelium perme-
ability and is repeatedly used over extremely long periods of
time.
8 Complementarily, the 24 h recovery appeared justiﬁed as
for the monolayer cultures for evaluating late effects, either
in terms of possible compensation and recovery or as an
ampliﬁcation of toxic reactions.
In conclusion, our results using the new 3D-HCE model for
evaluating BAC-containing prostaglandin analogues and PF-
taﬂuprost were in accordance with previously published works
investigating BAC toxicity. The present study provides a valu-
able method to evaluate the impacts of eye-drops in vitro, being
more accurate than single monolayers and easier to perform
than animal models. The development of 3D-HCEs thus
enriches the existing models to study the bioactivity of eye-
drops in the cornea by investigating and quantifying a set of
cellular functions such as cellular viability, inﬂammation,
proliferation, apoptosis or cell junctions.
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